Tharimmune (THAR)

• Market cap: $102M
• 1 day: -3.32%
• 5 days: -32.01%
• 1 month: -6.73%
• 3 months: 120.45%
• 6 months: 107.86%
• Year to date: 41.95%
• 1 year: 30.49%
• 5 years: -99.78%
• 10 years: -99.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Employees: 3